New therapies for advanced cancers are being developed, focusing on precision medicine for underserved patient subpopulations. Promising novel treatments, such as antibody-drug conjugates and Radioligand are increasingly featured in clinical trial.The Oncology Compass report provides a comprehensive analysis of the rapidly growing oncology market, driven by a significant rise in spending.The report emphasizes the approval of breakthrough therapies, such as Antibody-Drug Conjugates (ADCs) and Radioligand therapies, by the FDA and EMA. It also covers M&A trends and the transformative potential of Generative AI in enhancing oncology diagnostics, early detection, and personalized treatments.